瑞士市场报道
November 16, 2018 / 9:43 PM / a month ago

BRIEF-FDA Approves Novartis Drug Promacta® For First-Line Saa And Grants Breakthrough Therapy Designation For Additional New Indication

1 分钟阅读

Nov 16 (Reuters) - Novartis AG:

* FDA APPROVES NOVARTIS DRUG PROMACTA® FOR FIRST-LINE SAA AND GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR ADDITIONAL NEW INDICATION Source text for Eikon: Further company coverage:

我们的标准：汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below